Company intelligence / Profile preview

ReadeRx Therapeutics

Ownership: Private
Development stage: Preclinical

Overview

ReadeRx Therapeutics develops small molecule inhibitors targeting the RNA binding protein IGF2BP1, a promising approach for cancer therapy. IGF2BP1, an oncofetal RNA binding protein, regulates key pro-oncogenic RNAs and its inhibition may disrupt tumorigenic processes. The company appears to be in preclinical development with no reported clinical results yet[1][2][4].

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Beyond the preview

Go deeper on ReadeRx Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ReadeRx Therapeutics.

Explore the full profile